NEW YORK (GenomeWeb) – Researchers associated with protein biomarker firm Cleveland Diagnostics have published interim data from a clinical study investigating the performance of the company's IsoPSA test for prostate cancer.

The analysis of 132 patients found that the IsoPSA test significantly outperformed standard PSA testing both for detection of prostate cancer and assessing the likelihood of aggressive disease.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.